Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchiveTrupanion Announces 2026 truFame Winners

Live News EQUITY FLASH L impact Oct 14, 2026, 04:15 PM UTC

Trupanion Announces 2026 truFame Winners

Trupanion announced the winners of its 2026 truFame program.

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

TRUP

Related stories

Crisil Announces Rs 17 Per Share Dividend and Record Date Crisil announced a Rs 17 per share dividend and record date alongside its second-quarter results. Net profit rose 20.2% year on year in the quarter ended September 2026. M impact | EQUITY | Oct 24, 2026, 03:52 PM UTC Godrej Properties Q2 Profit Falls 62% to Rs.154.15 Crore Godrej Properties reported consolidated net profit of Rs.154.15 crore for the quarter ended September, down 62% year over year. Its shares closed 4.23% lower on Friday. M impact | EQUITY | Oct 24, 2026, 03:52 PM UTC WULF Shares Close at Six-Month Weekly Low as Credit Line Expands TeraWulf shares closed at their lowest weekly level in at least six months on Friday, after falling more than 60% since June. The company increased its senior secured revolving cre M impact | EQUITY | Oct 24, 2026, 03:43 PM UTC Amgen Says Imdelltra Combo Reduced Death Risk 58% in First-Line Lung Cancer M impact | EQUITY | Oct 24, 2026, 02:36 PM UTC AstraZeneca Bladder Cancer Treatment Reduced Recurrence Risk 49% Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced recurrence risk by 49% and risk of death by 42% in muscle-invasive bladder cancer. M impact | EQUITY | Oct 24, 2026, 02:36 PM UTC AstraZeneca VOLGA Phase III Trial Meets EFS and OS Endpoints AstraZeneca said perioperative Imfinzi plus neoadjuvant enfortumab vedotin met VOLGA Phase III endpoints in MIBC. The trial cut EFS risk by 49% (HR 0.51; p<0.0001) and death risk b M impact | EQUITY | Oct 24, 2026, 02:30 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Market Context
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.